Meeting
2022 ASCO Genitourinary Cancers Symposium
Health-related quality of life as a prognostic indicator of biochemical recurrence free survival in high-risk prostate cancer patients following radical prostatectomy.
Authors
Thilo Westhofen
Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
Thilo Westhofen , Alexander Buchner , Boris Schlenker , Armin Becker , Christian G. Stief , Alexander Kretschmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 235)
DOI
10.1200/JCO.2022.40.6_suppl.235
Abstract #
235
Poster Bd #
K10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.
First Author: Stephen J. Freedland
Poster
2023 ASCO Genitourinary Cancers Symposium
Validation of baseline health-related quality of life as prognostic indicator for survival outcome in men with intermediate risk prostate cancer undergoing radical prostatectomy.
First Author: Thilo Westhofen
Poster
2021 Genitourinary Cancers Symposium
Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.
First Author: Bruce J. Trock
Poster
2020 Genitourinary Cancers Symposium
Biochemical relapse in very high-risk prostate cancer after radical prostatectomy and DC-vaccine loaded with tumor RNA, hTERT, and survivin.
First Author: Wolfgang Lilleby